文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET/CT影像组学预测多发性骨髓瘤高危细胞遗传学异常的可行性研究

A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma.
PubMed 文献 · EJNMMI Res · 2025-10-15

本研究基于初治多发性骨髓瘤患者治疗前18F-FDG PET/CT影像组学特征,构建并验证预测高危细胞遗传学异常(HRCAs)的模型。在42个候选模型中,利用PET活动病灶特征的决策树分类器在验证队列中表现最优(AUC=0.89),显著优于PET指标模型(AUC=0.84)和临床模型(AUC=0.74),并能将患者分层为高危和低危组,两组PFS和OS差异显著。

要点

  • 基于PET活动病灶特征的决策树模型预测HRCAs的AUC达0.89,优于PET指标模型和临床模型。
  • 模型分层的高危组PFS(24.5个月 vs 29个月,p=0.0360)和OS(33.5个月 vs 50个月,p=0.0023)均显著更差。
  • SHAP分析显示PET衍生特征是模型预测能力的最重要贡献因素。

核心结论

  • 基于治疗前18F-FDG PET/CT影像组学的决策树模型可作为无创影像生物标志物预测多发性骨髓瘤高危细胞遗传学状态并辅助预后分层。

研究设计与样本

  • 单中心可行性研究,纳入初治多发性骨髓瘤患者,基于治疗前18F-FDG PET/CT影像组学特征构建并验证预测HRCAs的模型,从42个候选模型中筛选最优模型。

主要发现

  • 在42个候选模型中,利用PET活动病灶特征的决策树分类器在验证队列中表现最优,AUC为0.89。
  • 该模型显著优于PET指标模型(AUC=0.84)和临床模型(AUC=0.74)。
  • SHAP分析识别PET衍生特征为模型预测能力的最重要贡献因素。
  • 模型分层的高危组PFS显著更短(中位PFS:高危24.5个月 vs 低危29个月,p=0.0360)。
  • 模型分层的高危组OS显著更短(中位OS:高危33.5个月 vs 低危50个月,p=0.0023)。

关键数值与推荐

  • 决策树分类器模型在验证队列中AUC=0.89。
  • PET指标模型AUC=0.84,临床模型AUC=0.74。
  • 高危组 vs 低危组:中位PFS 24.5个月 vs 29个月(p=0.0360);中位OS 33.5个月 vs 50个月(p=0.0023)。

临床怎么用

  • 对于初治多发性骨髓瘤患者,可利用治疗前18F-FDG PET/CT影像组学无创预测高危细胞遗传学状态,辅助预后分层。
  • 该模型尚需大规模多中心前瞻性验证以确认其用于个体化治疗决策的效用。

局限性

  • 研究结论指出需进一步开展大规模、多中心前瞻性验证以确认其效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple myeloma (MM) is a heterogeneous malignancy with prognosis significantly affected by high-risk cytogenetic abnormalities (HRCAs). Traditional detection using fluorescence in situ hybridisation is invasive and limited in capturing disease heterogeneity. We aimed to develop and validate radiomics model based on pretreatment [18F] fluoro-deoxyglucose (FDG) positron emission tomography/computed tomographic (18F-FDG PET/CT) imaging to non-invasively predict HRCAs in newly diagnosed MM patients. RESULTS: Among the 42 candidate models, the Decision Tree classifier utilizing PET active lesions features demonstrated optimal performance in the validation cohort, exhibiting excellent predictive ability (Area Under the Curve (AUC) = 0.89), significantly outperforming the PET metrics model (AUC = 0.84) and clinical model (AUC = 0.74). SHapley Additive exPlanations analysis identified the PET-derived feature as the most important contributor to the model's predictive capacity. The model stratified patients into high-risk and low-risk groups, with the high-risk group exhibiting significantly worse PFS and OS (median PFS: high-risk 24.5 months vs. low-risk 29 months; p = 0.0360; median OS: high-risk 33.5 months vs. low-risk 50 months; p = 0.0023). CONCLUSION: As a non-invasive imaging biomarker, PET/CT radiomics holds potential for predicting high-risk cytogenetic status and facilitating patient prognosis stratification Further large-scale, multi-center prospective validations are essential to confirm its utility for personalized therapeutic decision-making in MM.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chen H, Han J, Huang H, et al. A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma. EJNMMI Res. 2025. PMID: 41091252. doi:10.1186/s13550-025-01321-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。